By The Washington Post and IBJ Staff The shortage of Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday ...

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses ...

Eli Lilly & Co.’s diabetes and weight-loss drugs Mounjaro and Zepbound are no longer in short supply in the US, which means compounding pharmacies must stop making less expensive copycat ...

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as supply of both medicines has largely recovered ...

Eli Lilly’s (NYSE:LLY) popular weight loss therapy, tirzepatide, has officially come out of shortage in the U.S., according to the latest data from the U.S. Food and Drug Administration (FDA) on ...

Zepbound drugmaker Eli Lilly is working to increase its weight loss drug supply. But some steps to get there, including building a new plant, will take months to execute.

News weighs on stocks of companies offering alternatives and some smaller ones developing their own drugs The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs ...

All doses of Eli Lilly’s weight loss drugs Zepbound and Mounjaro are available in the U.S. after more than a year of being in shortage, according to the FDA's medication shortage database.

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, threatening to upend the many knockoffs that became popular when patients ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in ...